Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: A meta-analysis of the published literature

Abstract Objective It remains controversial whether intensified chemotherapy with hematopoietic progenitors (ICHP) is effective for small-cell lung cancer. This meta-analysis was performed to evaluate the efficacy and safety of ICHP in patients with small-cell lung cancer. Methods MEDLINE and EMBASE...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2009-08, Vol.65 (2), p.214-218
Main Authors: Jiang, J, Shi, H.-Z, Deng, J.-M, Liang, Q.-L, Qin, S.-M, Wu, C
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Chemotherapy
Combined Modality Therapy
Hematology, Oncology and Palliative Medicine
Hematopoietic progenitor cells
Hematopoietic Stem Cell Transplantation
Humans
Lung Neoplasms - therapy
Medical sciences
Pneumology
Pulmonary/Respiratory
Randomized Controlled Trials as Topic
Small Cell Lung Carcinoma - therapy
Small-cell lung cancer
Tumors
Tumors of the respiratory system and mediastinum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective It remains controversial whether intensified chemotherapy with hematopoietic progenitors (ICHP) is effective for small-cell lung cancer. This meta-analysis was performed to evaluate the efficacy and safety of ICHP in patients with small-cell lung cancer. Methods MEDLINE and EMBASE databases were searched for English-language studies published through October 12, 2008. Randomized phase II and III clinical trials comparing ICHP with control therapy. Response rates, overall survival, and toxicity were analyzed. Results Five assessable trials were identified including 641 patients. No significant increase in the odds ratio for response was attributable to ICHP (odds ratio, 1.29; 95% confidence interval, 0.87–1.93; p = 0.206). No statistically significant increase in overall survival was found when ICHP were compared to control regimens (hazard ratio, 0.94; 95% confidence interval, 0.80–1.10; p = 0.432). The toxicity of ICHP was significantly higher for hematologic toxicity, including hemoglobin nadir and platelet nadir. Conclusions ICHP was not superior to control chemotherapy in terms of both objective response and overall survival, and was related to more significant hemoglobin nadir and platelet nadir.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2008.11.011